|
|||||
|
|
Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B-LONG trial |
|
| Authors: | Robert F. Sidonio Jr Sandra Casiano Aletta Falk Arman Altincatal Suresh Katragadda Elena Santagostino Jerzy Windyga |
| Affiliation: | 1. Aflac Cancer and Blood Disorders, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA;2. Sanofi, Cambridge, Massachusetts, USA;3. Swedish Orphan Biovitrum AB, Stockholm, Sweden;4. Sanofi, Waltham, Massachusetts, USA;5. Swedish Orphan Biovitrum AG, Basel, Switzerland;6. Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland |
| Abstract: | |
| Keywords: | clinical study factor IX factor IX Fc fusion protein haemophilia B pharmacokinetics |